Semaglutide Asthma Link
New Study Links Semaglutide To Significantly Fewer Asthma Attacks And COPD Flare-Ups
Anonymous
Key Points
1
The researchers compared people starting GLP-1 treatments with similar patients prescribed sulfonylureas, another class of diabetes medication, across four parallel studies.
2
The study was presented by Dr Bohee Lee at the European Respiratory Society Congress; it was led by Professor Chloe Bloom of Imperial College London.
3
Researchers said the possible respiratory benefit may relate to earlier evidence that GLP-1 drugs have anti-inflammatory effects and can improve lung-related outcomes, although asthma and COPD outcomes had not been included in previous GLP-1 clinical trials.
4
Experts cautioned that the observational analysis may not fully account for differences in treatment adherence or individual clinical care, even though the active-comparator design adjusted for factors including body-mass index and smoking.
5
Professor Stephen Burgess of the University of Cambridge noted that the findings were presented at a conference rather than in a fully peer-reviewed paper, and said randomized clinical trials are still needed to determine whether semaglutide directly prevents respiratory attacks.
Semaglutide, the drug behind Ozempic and Wegovy, may protect against asthma attacks far more than doctors realized. Fox 13 Now reported that a new study found people taking the medication experienced nearly 40% fewer asthma attacks and 20% fewer COPD flare-ups compared to those on other diabetes drugs. The research analyzed thousands of UK patient records and was presented at the European Respiratory Society Congress in Spain.
But experts urged caution: the study shows an association, not proof that semaglutide prevents respiratory attacks. US News noted that Professor Stephen Burgess of Cambridge warned the findings need randomized clinical trials before doctors change treatment guidelines. Patients should not start or change GLP-1 drugs specifically for asthma relief without talking to their doctor first.
A Surprise Discovery in UK Patient Records
The research, led by Professor Chloe Bloom at Imperial College London, compared about 20,000 to 22,000 patients in each of four separate studies. Medindia reported that researchers tracked people who started semaglutide against similar patients prescribed sulfonylureas, another diabetes medication class. The semaglutide group showed dramatically fewer respiratory attacks, with the strongest benefit among patients with more severe asthma.
The 40% reduction in asthma attacks was the headline finding. 3 News Now confirmed that the study also identified a 20% drop in COPD flare-ups among semaglutide users. These numbers emerged from analyzing electronic health records—real patient data from everyday medical practice, not a controlled lab setting.
Anti-Inflammatory Powers May Explain the Link
Scientists suspect semaglutide's respiratory benefits stem from its anti-inflammatory effects. Medindia explained that GLP-1 drugs have shown promise for lung-related outcomes in prior studies, though asthma and COPD have never been studied in major clinical trials. The drug works by mimicking a natural hormone that controls blood sugar and appetite. This same mechanism appears to calm inflammation in the airways.
The connection makes biological sense. Asthma and COPD both involve airway inflammation. If semaglutide reduces inflammation throughout the body—as earlier research suggests—it could naturally ease breathing problems. But this remains a hypothesis waiting for rigorous proof through controlled trials.
Why Scientists Still Demand Controlled Trials
Professor Stephen Burgess of Cambridge raised a critical point: the study was presented at a conference, not yet published in a peer-reviewed journal. US News reported his concern that observational research like this cannot fully account for differences in how well patients followed their treatment plans. Even with statistical adjustments for factors like BMI and smoking, hidden differences between groups could explain the findings.
Real clinical trials—where doctors randomly assign patients to either semaglutide or placebo—remain the gold standard. Without them, doctors cannot confidently say semaglutide prevents asthma attacks. The association is intriguing, but association is not cause-and-effect. More research must come first.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
43
Reach
62
A
AnonymousAuthor
